Sight Sciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Badawi
- Full Time Employees
- 216
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 4040 Campbell Avenue Menlo Park CA United States of America 94025
- IPO Date
- Jul 15, 2021
- CIK
- 0001531177
- Website
- sightsciences.com
- Similar Companies
- Business
- Sight Sciences, Inc. (SGHT) develops and commercializes ophthalmic medical devices focused on surgical and nonsurgical technologies for treating prevalent eye diseases including glaucoma and dry eye; its core products comprise the OMNI Surgical System, a minimally invasive glaucoma surgery (MIGS) device indicated for canaloplasty and trabeculotomy to target multiple outflow pathway resistance points, and the TearCare System, an office-based therapy addressing meibomian gland dysfunction as the root cause of dry eye disease; additional offerings include the SION Surgical System for enhanced goniotomy procedures. The company operates primarily in two segments, Surgical Glaucoma and Dry Eye, targeting ophthalmologists, optometrists, and specialized eye care clinics across the United States with a direct sales force supported by clinical education; it generates revenue through device sales and procedure-related royalties while maintaining outsourced manufacturing for flexibility. Founded in 2011 and headquartered in Menlo Park, California, Sight Sciences continues to invest heavily in research and development, with 2023 expenditures reaching $24.7 million to advance MIGS and dry eye innovations amid a competitive landscape featuring players like Glaukos and Alcon. Recent developments include the closing of a senior secured credit facility of up to $65 million with Hercules Capital in May 2024 to bolster its balance sheet and strategic execution, alongside reporting third-quarter 2025 financial results that prompted an upward revision to full-year 2025 revenue guidance, reflecting sustained procedural adoption and market expansion.
Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
Sight Sciences to Present at Two Upcoming Investor Conferences
Sight Sciences Announces the Release of its Sustainability Report
Sight Sciences Announces the Release of its Sustainability Report
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
Insider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells $10,615.30 in Stock
Sight Sciences (NASDAQ:SGHT) CTO Sells $28,424.64 in Stock
Paul Badawi Sells 29,244 Shares of Sight Sciences (NASDAQ:SGHT) Stock
Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance